The substantial investments in human genetics and genomics made over the past three
decades were anticipated to result in many innovative therapies. Here we investigate the …

version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

ABSTRACT Abbreviations: A1C= hemoglobin A1C; AACE= American Association of Clinical
Endocrinologists; ABCD= adiposity-based chronic disease; ACCORD= Action to Control …

Background Inclisiran, an siRNA administered twice-yearly, significantly reduced LDL
cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran translates into …

Background Patients who have had an acute coronary syndrome are at high risk for
recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a …

The recommendations listed in the present guideline are, whenever possible, evidence
based. An initial extensive evidence review, which included literature derived from research …

Objective The objective is to formulate clinical practice guidelines for the treatment of
diabetes in older adults. Conclusions Diabetes, particularly type 2, is becoming more …

Background Lipoprotein (a) concentration is associated with cardiovascular events.
Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein (a) …

Surveys and registries are needed to verify that real-life daily practice is in keeping with what
is recommended in the guidelines, thus completing the loop between clinical research …

Atherosclerosis, the formation of fibrofatty lesions in the artery wall, causes much morbidity
and mortality worldwide, including most myocardial infarctions and many strokes, as well as …